论文部分内容阅读
WTO将中国医药企业放到了显微镜下,所有的伤疤都一览无遗:在众多的制药企业中,大型企业仅有314家,其余均为中小型企业,规模效益差。我国6000多家医药企业年利润总和不抵《财富》五百强药企一家公司的利润额;2000年,世界十大制药公司研发费用占其销售收入的平均比重为69.91％,而我国国内制药企业研发费用的投入最多不超过3％,一般仅为0.5％-1.0％:企业质量不高,多数企业未通过GMP(药品生产质量管理规范)、GSP(药品经营质量规范)认证。
WTO put the Chinese pharmaceutical enterprises under the microscope, all the scars are at a glance: among the large number of pharmaceutical companies, only 314 large enterprises, the rest are small and medium enterprises, economies of scale. The total annual profit of more than 6,000 pharmaceutical companies in our country can not reach the profit of one company of Fortune 500 pharmaceutical companies. In 2000, the top 10 pharmaceutical companies in the world accounted for 69.91% of the total R & D expenses, while the domestic pharmaceutical Most enterprises do not pass the GMP (Pharmaceutical Production Quality Management Specification) and GSP (Pharmaceutical Business Quality Standard) certification.